GlykoGen Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $86.3K

  • Investors
  • 4

GlykoGen General Information

Description

Developer of anti-glycan antibodies designed to produce fighting agents for cancer treatment and diagnostics. The company's engineered monoclonal antibodies are produced using their novel immunization process to target carbohydrates found on the surface of cancerous cells, enabling healthcare organizations and pharmaceutical companies to target hard-to-treat cancers, including pancreatic cancer.

Contact Information

Website
www.glykogen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The James Hutton Institute
  • Craigiebuckler
  • Aberdeen AB15 8QH
  • Scotland, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • The James Hutton Institute
  • Craigiebuckler
  • Aberdeen AB15 8QH
  • Scotland, United Kingdom

GlykoGen Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlykoGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 30-Jun-2022 $86.3K Completed Generating Revenue
5. Later Stage VC 12-Oct-2021 Completed Generating Revenue
4. Early Stage VC 12-Nov-2020 Completed Generating Revenue
3. Early Stage VC 16-Apr-2019 Completed Generating Revenue
2. Early Stage VC 18-Apr-2018 $495K $495K Completed Generating Revenue
1. Grant 01-Jul-2016 $141K Completed Startup
To view GlykoGen’s complete valuation and funding history, request access »

GlykoGen Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 583,554 $0.012330 $1.23 $1.23 1x $1.23 36.62%
To view GlykoGen’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

GlykoGen Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

GlykoGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201611013-D0 Antibody production Inactive 24-Jun-2016

GlykoGen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GlykoGen Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Equity Gap Angel Group Minority
Highland Venture Capital Venture Capital Minority
Scottish Enterprise Government Minority
To view GlykoGen’s complete investors history, request access »

Ready to get started?

Request a free trial

GlykoGen FAQs

  • When was GlykoGen founded?

    GlykoGen was founded in 2016.

  • Where is GlykoGen headquartered?

    GlykoGen is headquartered in Aberdeen, United Kingdom.

  • What is the size of GlykoGen?

    GlykoGen has 2 total employees.

  • What industry is GlykoGen in?

    GlykoGen’s primary industry is Drug Discovery.

  • Is GlykoGen a private or public company?

    GlykoGen is a Private company.

  • What is the current valuation of GlykoGen?

    The current valuation of GlykoGen is .

  • What is GlykoGen’s current revenue?

    The current revenue for GlykoGen is .

  • How much funding has GlykoGen raised over time?

    GlykoGen has raised $1.01M.

  • Who are GlykoGen’s investors?

    , Equity Gap, Highland Venture Capital, and Scottish Enterprise have invested in GlykoGen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »